Why would the outcome from the other biotech's BLA submission impact Cynata's trial? The other biotech is seeking approval in paediatric steroid-resistant acute GvHD, while Cynata is starting a trial for High-risk acute GvHD (NOT STEROID RESISTANT). The two therapies are clearly not the same. One market is far larger than the other, even if the other biotech was eligible to treat adults, too.
Ann: Initial Director's Interest Notice - Kilian Kelly, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $62.06K | 386.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 158709 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 28900 | 4 |
View Market Depth
| Last trade - 14.47pm 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |